Sjögren’s syndrome patients presenting with hypergammaglobulinemia are relatively unresponsive to cevimeline treatment

Sjögren’s syndrome (SS) is a systemic autoimmune disease characterized by sicca symptoms, including dry eyes and dry mouth. Cevimeline is used for the treatment of dry mouth in patients with SS. Here we prospectively tested the clinical effectiveness of cevimeline at increasing saliva secretion in patients with SS, and the results were compared with the clinical parameters of the patients. Saliva secretion was increased >160% in 17 of 30 (56.7%) patients (P < 0.005). When the clinical parameters were compared between the patients who responded to cevimeline treatment and those who did not respond to the treatment, the frequency of patients presenting with hypergammaglobulinemia was significantly higher in the nonresponder group (P < 0.05). It thus appears that cevimeline is effective in SS patients with milder disease activity.

[1]  T. Dörner,et al.  Targeting CD22 as a strategy for treating systemic autoimmune diseases , 2007, Therapeutics and clinical risk management.

[2]  K. Brokstad,et al.  Impaired salivary gland function in NOD mice: association with changes in cytokine profile but not with histopathologic changes in the salivary gland. , 2006, Arthritis and rheumatism.

[3]  H. Moutsopoulos,et al.  The management of Sjögren's syndrome , 2006, Nature Clinical Practice Rheumatology.

[4]  S. Rogers,et al.  Antimuscarinic antibodies in primary Sjögren's syndrome reversibly inhibit the mechanism of fluid secretion by human submandibular salivary acinar cells. , 2006, Arthritis and rheumatism.

[5]  P. Manganelli,et al.  Apoptosis and Sjögren syndrome. , 2003, Seminars in arthritis and rheumatism.

[6]  A. Berra,et al.  Role of salivary IgA in the pathogenesis of Sjögren syndrome. , 2002, Clinical immunology.

[7]  E. Tindall,et al.  Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial. , 2002, Archives of internal medicine.

[8]  R. Fox.  Use of cevimeline, a muscarinic M1 and M3 agonist, in the treatment of Sjögren's syndrome. , 2002, Advances in experimental medicine and biology.

[9]  J. Murube,et al.  The lacunar sulci: a new test to measure the shrinkage of ocular surface, and its relation with the number of goblet cells. , 2002, Advances in experimental medicine and biology.

[10]  S. Miyawaki.  [Revised Japan criteria for Sjögren syndrome]. , 2000, Ryumachi. [Rheumatism].

[11]  P. Fox,et al.  Opening the flood gates: interferon-alpha treatment for Sjögren's syndrome. , 2000, BioDrugs.

[12]  K. Shiozawa,et al.  Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjögren's syndrome. , 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[13]  A. Geiser,et al.  Up-regulation of cytokine mRNA, adhesion molecule proteins, and MHC class II proteins in salivary glands of TGF-beta1 knockout mice: MHC class II is a factor in the pathogenesis of TGF-beta1 knockout mice. , 1997, Journal of immunology.

[14]  E. Borda,et al.  Circulating antibodies against rat parotid gland M3 muscarinic receptors in primary Sjögren's syndrome , 1996, Clinical and experimental immunology.

[15]  N. Ogawa,et al.  Analysis of transforming growth factor beta and other cytokines in autoimmune exocrinopathy (Sjögren's syndrome). , 1995, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[16]  T. Masuhara,et al.  Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: identification of a potential therapeutic agent for treatment of Sjörgen's syndrome. , 1994, General pharmacology.

[17]  P. Kohler,et al.  A quantitative test for xerostomia. The Saxon test, an oral equivalent of the Schirmer test. , 1985, Arthritis and rheumatism.